Methods for modulating host cell surface interactions with SARS-CoV-2
AssigneeGenentech, Inc.
InventorNadia Martinez-Martin
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating or preventing SARS-CoV-2 infection comprising modulating interactions between the SARS-CoV-2 spike protein and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.
Claims20
A method of treating an individual having a SARS-CoV-2 infection comprising administering to the individual an effective amount of a contactin-1 (CNTN1) antagonist, an interleukin 12 receptor subunit beta 1 (IL12RB1) antagonist, or an interleukin 1 receptor accessory protein like 2 (IL1RAPL2) antagonist.
A method of reducing SARS-CoV-2 attachment to a cell of an individual comprising administering to the individual an effective amount of a CNTN1 antagonist, an IL12RB1 antagonist, or an IL1RAPL2 antagonist.
A method of prophylaxis against secondary infection of nervous tissue in an individual having a SARS-CoV-2 infection comprising administering to the individual an effective amount of a CNTN1 antagonist or an IL1RAPL2 antagonist.
A method of prophylaxis against secondary infection of immune cells and/or lymphoid tissue in an individual having a SARS-CoV-2 infection comprising administering to the individual an effective amount of an IL12RB1 antagonist.
A method of prophylaxis against secondary infection of the lungs in an individual having a SARS-CoV-2 infection comprising administering to the individual an effective amount of a CNTN1 antagonist or an IL12RB1 antagonist.
A method of identifying a modulator of the interaction between the SARS-CoV-2 S protein and CNTN1, IL12RB1, or IL1RAPL2, the method comprising:
- (a) providing a candidate modulator;
- (b) contacting the SARS-CoV-2 S protein RBD with CNTN1, IL12RB1, or IL1RAPL2 in the presence or absence of the candidate modulator under conditions permitting the binding of the SARS-CoV-2 S protein RBD to CNTN1, IL12RB1, or IL1RAPL2;
- and
- (c) measuring the binding of the protein of the SARS-CoV-2 S protein RBD to CNTN1,IL12RB1, or IL1RAPL2, wherein an increase or decrease in binding in the presence of the candidate modulator relative to binding in the absence of the candidate modulator identifies the candidate modulator as a modulator of the interaction between the SARS-CoV-2 S protein and CNTN1, IL12RB1, or IL1RAPL2.
A pharmaceutical formulation comprising a modulator of the interaction between the SARS-CoV-2 S protein and CNTN1, IL12RB1, or IL1RAPL2, wherein the modulator causes a decrease in the binding of the SARS-CoV-2 S protein to CNTN1, IL12RB1, or IL1RAPL2 relative to binding in the absence of the modulator.
Dependencies are inferred from the claim text.